INBX · Inhibrx Biosciences, Inc. · Metrics
Market Cap
$1.54B
Shares
14.72M
INBX metrics
60 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$109.35
Market cap
$1.54B
Price action
20 metricsPrice change (1W)
+0.1%
Price change (30D)
+4.2%
Price change (3M)
+17.5%
Price change (6M)
+79.5%
Price change (YTD)
+38.4%
Price change (1Y)
+310.3%
Trailing year
Price change (5Y)
—
52-week high
$141.84
52-week low
$26.65
Change from 52-week high
-22.9%
Change from 52-week low
+310.3%
Annualized volatility
130.1%
Annualized volatility (3M)
64.2%
Beta
2.5
RSI (14D)
51.4
Price vs SMA 50
+10.2%
Price vs SMA 200
+21.3%
Avg volume (3M)
316,190
Relative volume
1.5
Average dollar volume
$31.98M
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
14.72M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
-8.6%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-9.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-09-08
Profitability
9 metricsGross margin
—
Operating margin
-10,386.5%
Trailing 12 months
Net margin
-10,773.5%
Gross profit (TTM)
—
Operating profit (TTM)
−$127.81M
Net income (TTM)
−$138.18M
Trailing 12 months
Diluted EPS (TTM)
$-8.88
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-100.0%
Year over year
Net income growth YoY
-108.3%
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
-108.0%
Shares change YoY
+1.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-89.6%
Debt / equity
—
Current ratio
5.1
EBITDA (TTM)
−$125.61M
Free cash flow (TTM)
−$131.90M
Quick ratio
5.1
Interest coverage
-8.2
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$42.94M
Latest balance sheet
Cash & equivalents
$133.34M
Total assets
$154.22M
Total debt
$176.28M
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$131.89M
Capital expenditures (TTM)
$10,000
R&D (TTM)
$103.00M
SG&A (TTM)
—
Stock compensation (TTM)
$11.68M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
165
13F filer change QoQ
+27
Institutional ownership
99.9%
Short interest
3 metricsShort interest
22.4%
Latest settlement · 10.4 days to cover
Days to cover
10.4d
Short-squeeze score
77 / 100
Insider activity
2 metricsNet insider buying (90D)
$3.72M
Insider-sentiment score
92 / 100
Risk flags
1 metricsGoing concern
—